Randomized Controlled Trial Examining the Efficacy of Botulinum Toxin in Biopsy Scar Minimization
试验速览
- 阶段
- 2 期
- 状态
- 进行中(未招募)
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- Primary Outcome Measure
研究概览
简要总结
The proposed study seeks to evaluate the scar reduction capacity of BTA on excision/biopsy wounds compared to the control (normal saline) in a double-blinded randomized control trial. It will expand upon previous studies that have already demonstrated the safety and good tolerance profile of BTA. We will be conducting a split-scar study/study involving two biopsy sites in a singular patient, allowing them to serve as their own control. In keeping with the results from previously conducted studies, we hypothesize that the wounds treated with BTA will have significantly less evidence of scar formation than those sites treated with normal saline.
详细描述
The process of scar formation is denoted by three stages: inflammatory, proliferative, and remodeling. The former phase is characterized by the activation of the extrinsic clotting pathway and subsequent materialization of a fibrin plug, after which neutrophils facilitate the degradation of pathogens and secretion of signaling molecules that commence the proliferative phase. The fibrin plug is then replaced by granulation tissue comprised of macrophages, fibroblast, and endothelial cells in the proliferative phase. Through the release several growth factors, existing macrophages induce laying down of type III collagen by fibroblasts, and keratinocytes work in tandem to approximate wound edges. Lastly, during the remodeling phase, cellular apoptosis causes granulation tissue formation to subside, type III collagen is replaced by a more durable collagen type I, and myofibroblasts help to condense the scar size.1,2
While scarring in its non-pathological forms is an innate and appropriate bodily response to cutaneous injury, scar development and persistence can have negative physical and psychological implications, including decreased range of motion secondary to contracture, disfigurement, and impaired quality of life.1,3-5 Thus, for medical and cosmetic purposes alike, curtailing scar formation is important aspect of patient management, and treatment aimed at both prevention and resolution is an evolving subject in the medical discourse. Credence has been given to the use of botulinum toxin A (BTA) in scar minimization, a more novel therapy, and has proved efficacious in several studies including those examining BTA in the treatment of keloids and hypertrophic scars, mammoplasty and abdominoplasty surgery scars, and post-operative scars generally.6-9 The suggested mechanisms for this phenomenon involve inhibition of pre-synaptic acetylcholine channels that lead to muscle paralysis and relaxation of perpendicular wound tension; this particular mechanism is likewise theorized to mitigate collagen overproduction. Another hypothesis for explaining the ability of BTA to reduce scar appearance is the direct modulation of fibroblast activity.6
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Triple (Participant, Care Provider, Investigator)
盲法说明
The injector, assessor, patient, and outcome assessor will be blinded to the treatment side and placebo side of injection.
入排标准
- 年龄范围
- 18 Years 至 70 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy Individuals age 18 and older
- •Able to understand the requirements of the study and its associated risks
- •Able to complete and sign a consent form
排除标准
- •Allergy to botulinum toxin
- •Currently pregnant or breastfeeding
- •Myasthenia gravis
- •Previous injection of botulinum toxin in the specified treatment areas within 6 months prior to enrollment
- •Unable to follow up 6 months after biopsy procedure
- •Refusal to participate in the trial
- •History of keloid or hypertrophic scars
- •Eaton-Lambert Syndrome
- •Amyopathic Lateral Sclerosis
研究组 & 干预措施
Botulinum toxin
Biopsy site receiving botulinum toxin
Following the biopsy closures, one of two biopsy sites (left or right) will be selected to receive 30u (0.3cc) of botulinum toxin injected into the suture line at a depth of PPD bleb.
The treatment for each wound site will be randomized (left versus right) and blinded but consistent throughout dosing.
干预措施: Botulinum Toxin (Drug)
Placebo
Placebo Comparator: Biopsy site receiving placebo
Following the biopsy closures, the other biopsy site will receive 30u (0.3cc) of bacteriostatic normal saline injected into the suture line at a depth of PPD bleb.
干预措施: Normal saline (Drug)
结局指标
主要结局
Primary Outcome Measure
时间窗: 6 months
Modified Patient and Observer Scar Assessment Scale v2.0 (POSAS)
Primary Outcome Measure
时间窗: 3 months
Modified Patient and Observer Scar Assessment Scale v2.0 (POSAS)
次要结局
未报告次要终点
研究者
David M. Ozog
Department Chair
Henry Ford Health System
